CAJ | 학술논문

目的：检测高迁移率族蛋白A2(high mobility group A2, HMGA2)在乳腺癌中的表达,分析其与临床病理特征的关系,探讨HMGA2在乳腺癌不同分子亚型中的表达。方法采用免疫组化EliVison两步法检测58例乳腺癌中HMGA2蛋白的表达。结果(1)管腔A、管腔B、HER-2过表达、基底细胞样及未分类型乳腺癌中HMGA2阳性率分别为0、62．5%、60．0%、100．0%及80．0%(三阴型92．3%),差异有显著性(P<0．01)。 HMGA2的高表达与三阴型乳腺癌相关(P<0．01)。(2)HMGA2的表达与组织学分级及淋巴结转移相关( P<0．05),与肿瘤大小、患者年龄无关；与 Ki-67、CK5/6及 EGFR表达呈正相关( P<0．05),与ER及PR表达呈负相关(P<0．01)。结论乳腺癌中HMGA2蛋白的表达与组织学分级、淋巴结转移、Ki-67、CK5/6及EGFR表达呈正相关,与ER、PR表达呈负相关。三阴型分子亚型有更高的HMGA2蛋白表达,HMGA2有望成为三阴型乳腺癌的治疗靶点。
목적：검측고천이솔족단백A2(high mobility group A2, HMGA2)재유선암중적표체,분석기여림상병리특정적관계,탐토HMGA2재유선암불동분자아형중적표체。방법채용면역조화EliVison량보법검측58례유선암중HMGA2단백적표체。결과(1)관강A、관강B、HER-2과표체、기저세포양급미분류형유선암중HMGA2양성솔분별위0、62．5%、60．0%、100．0%급80．0%(삼음형92．3%),차이유현저성(P<0．01)。 HMGA2적고표체여삼음형유선암상관(P<0．01)。(2)HMGA2적표체여조직학분급급림파결전이상관( P<0．05),여종류대소、환자년령무관；여 Ki-67、CK5/6급 EGFR표체정정상관( P<0．05),여ER급PR표체정부상관(P<0．01)。결론유선암중HMGA2단백적표체여조직학분급、림파결전이、Ki-67、CK5/6급EGFR표체정정상관,여ER、PR표체정부상관。삼음형분자아형유경고적HMGA2단백표체,HMGA2유망성위삼음형유선암적치료파점。
Purpose To detect high mobility group protein A2 (HMGA2) expression in breast cancer, and to analyze its relationship with clinicopathological features and the levels of HMGA2 in different molecular subtypes of breast carcinomas. Methods An immu-nohistochemical study was undertaken for measuring the levels of HMGA2 in 58 breast carcinomas. Results ( 1 ) The expression of HMGA2 was 0, 62. 5%, 60. 0%, 100. 0% and 80. 0% in Lum A, Lum B, HER-2-OE, basal-like breast carcinoma (BLBC) and un-classification phenotype respectively ( triple negative breast cancer, 92. 3%) . High expression of HMGA2 was associated with the tri-ple-negative breast cancer (TNBC) subtypes (P<0. 01). (2) An association was identified between high expression of HMGA2, and high tumor grade, lymph node metastasis (P<0. 05), positive Ki-67, CK5/6 and EGFR (P<0. 05), negative ER and PR (P<0. 01), but no association was observed for tumor size and patients’age. Conclusion An association is identified between high ex-pression, and high tumor grade, lymph node metastasis, positive Ki-67, EGFR and CK5/6, negative ER and PR, that means a high expression of HMGA2 is associated with an adverse outcome in breast cancer. High expression of HMGA2 are associated with the TNBC subtypes. Thus recognizing HMGA2 as a rational target in TNBC. The results of the study have implications for therapeutic target iden-tification and the design of future clinical trials for TNBC.